Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 16.20 is 161% above its 5-year average of 6.22, around the middle of its 5-year range (0.06–23.81).
As of the fiscal period ended Tuesday, June 30, 2026. 11.47% below its 12-month average of 18.30.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 16.20.
CURRENT RATIO
16.20
CURRENT RATIO AVG TTM
18.30
CURRENT RATIO AVG 3Y
9.31
CURRENT RATIO AVG 5Y
6.22
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-11.47%
CURRENT VS 3Y AVG
+74.03%
CURRENT VS 5Y AVG
+160.57%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.54
median of 732 covered companies
CURRENT VS SECTOR MEDIAN
+356.87%
vs the sector median at left
Market Cap
$6.49M
Current Ratio
10.21
TTM Avg
3.61
3Y Avg
3.34
5Y Avg
4.20
Market Cap
$6.43M
Current Ratio
0.70
TTM Avg
2.00
3Y Avg
1.31
5Y Avg
1.04
Market Cap
$6.80M
Current Ratio
2.61
TTM Avg
3.40
3Y Avg
4.86
5Y Avg
5.09
Market Cap
$7.08M
Current Ratio
0.31
TTM Avg
1.26
3Y Avg
1.91
5Y Avg
5.47
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aclarion, Inc. (ACON) | $6.74M | 16.20 | 18.30 | 9.31 | 6.22 |
| Co-Diagnostics, Inc. (CODX)vs › | $6.66M | 1.81 | 4.14 | 10.76 | 11.50 |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.49M | 10.21 | 3.61 | 3.34 | 4.20 |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.43M | 0.70 | 2.00 | 1.31 | 1.04 |
| Biomerica, Inc. (BMRA)vs › | $6.40M | 1.62 | 2.21 | 3.63 | 4.38 |
| Femasys Inc. (FEMY)vs › | $6.24M | 2.14 | 2.73 | 5.58 | 6.46 |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.80M | 2.61 | 3.40 | 4.86 | 5.09 |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.08M | 0.31 | 1.26 | 1.91 | 5.47 |
| KALA BIO, Inc. (KALA)vs › | $7.09M | 6.88 | 3.46 | 4.15 | 4.60 |
| Mangoceuticals, Inc. (MGRX)vs › | $6.98M | 0.18 | 0.90 | 2.08 | 1.78 |
Current Ratio
16.20
Quick Ratio
16.20
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 16.20 |
| 2026-03-31 | 19.65 |
| 2025-12-31 | 14.81 |
| 2025-09-30 | 17.01 |
| 2025-06-30 | 23.81 |
| 2025-03-31 | 21.68 |
| 2024-12-31 | 0.71 |
| 2024-09-30 | 2.80 |
| 2024-06-30 | 1.28 |
| 2024-03-31 | 2.08 |
| 2023-12-31 | 0.40 |
| 2023-09-30 | 0.15 |
| 2023-06-30 | 0.40 |
| 2023-03-31 | 0.92 |
| 2022-12-31 | 2.47 |
| 2022-09-30 | 2.46 |
| 2022-06-30 | 3.18 |
| 2022-03-31 | 0.06 |
| 2021-12-31 | 0.10 |
| 2021-09-30 | 0.12 |
| 2021-06-30 | 0.23 |
| 2021-03-31 | 0.00 |
| 2020-12-31 | 0.01 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
